Targeting on glycosylation of mutant FLT3 in acute myeloid leukemia

References

• Hospital MA, Green AS, Maciel TT, et al. FLT3 inhibitors: clinical potential in acute myeloid leukemia. Onco Targets Ther. 2017;10:607–615.
   PubMed Web of Science ®Google Scholar
• Acheampong DO, Adokoh CK, Asante DB, et al. Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy. Biomed Pharmacother. 2018;97:225–232.
   PubMed Web of Science ®Google Scholar
• Bose P, Vachhani P, Cortes JE. Treatment of relapsed/refractory acute myeloid leukemia. Curr Treat Options Oncol. 2017;18(3):17.
   PubMed Web of Science ®Google Scholar
• Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100(5):1532–1542.
   PubMed Web of Science ®Google Scholar
• Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 2003;3(9):650–665.
   PubMed Web of Science ®Google Scholar
• Volpe G, Clarke M, Garcia P, et al. Regulation of the Flt3 gene in haematopoietic stem and early progenitor cells. PloS one. 2015;10(9):e0138257.
   PubMed Web of Science ®Google Scholar
• Takahashi S. Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications. J Hematol Oncol. 2011;4(13). doi:10.1186/1756-8722-4-13.
   Web of Science ®Google Scholar
• Mackarehtschian K, Hardin JD, Moore KA, et al. Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity. 1995;3(1):147–161.
   PubMed Web of Science ®Google Scholar
• Vasconcelos-Dos-Santos A, Oliveira IA, Lucena MC, et al. Biosynthetic machinery involved in aberrant glycosylation: promising targets for developing of drugs against cancer. Front Oncol. 2015;5(138). doi:10.3389/fonc.2015.00138.
   PubMed Web of Science ®Google Scholar
• Mori S, Aoyagi Y, Yanagi M, et al. Serum N-acetylglucosaminyltransferase III activities in hepatocellular carcinoma. J Gastroenterol Hepatol. 1998;13(6):610–619.
   PubMed Web of Science ®Google Scholar
• Dube DH, Bertozzi CR. Glycans in cancer and inflammation–potential for therapeutics and diagnostics. Nat Rev Drug Discovery. 2005;4(6):477–488.
   PubMed Web of Science ®Google Scholar
• Hauselmann I, Borsig L. Altered tumor-cell glycosylation promotes metastasis. Front Oncol. 2014;4(28). doi:10.3389/fonc.2014.00028.
   PubMedGoogle Scholar
• Stowell SR, Ju T, Cummings RD. Protein glycosylation in cancer. Annu Rev Pathol. 2015;10:473–510.
   PubMed Web of Science ®Google Scholar
• Schmidt-Arras DE, Bohmer A, Markova B, et al. Tyrosine phosphorylation regulates maturation of receptor tyrosine kinases. Mol Cell Biol. 2005;25(9):3690–3703.
   PubMed Web of Science ®Google Scholar
• Schmidt-Arras D, Bohmer SA, Koch S, et al. Anchoring of FLT3 in the endoplasmic reticulum alters signaling quality. Blood. 2009;113(15):3568–3576.
   PubMed Web of Science ®Google Scholar
• Williams AB, Li L, Nguyen B, et al. Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia. Blood. 2012;120(15):3069–3079.
   PubMed Web of Science ®Google Scholar
• Rosnet O, Schiff C, Pebusque MJ, et al. Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood. 1993;82(4):1110–1119.
   PubMed Web of Science ®Google Scholar
• Grassot J, Mouchiroud G, Perriere G. RTKdb: database of receptor tyrosine kinase. Nucleic Acids Res. 2003;31(1):353–358.
   PubMed Web of Science ®Google Scholar
• van der Geer P, Hunter T, Lindberg RA. Receptor protein-tyrosine kinases and their signal transduction pathways. Annu. Rev. Cell Biol.. 1994;10:251–337.
   PubMedGoogle Scholar
• Griffith J, Black J, Faerman C, et al. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol Cell. 2004;13(2):169–178.
   PubMed Web of Science ®Google Scholar
• Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 1996;10(12):1911–1918.
   PubMed Web of Science ®Google Scholar
• Yokota S, Kiyoi H, Nakao M, et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia. 1997;11(10):1605–1609.
   PubMed Web of Science ®Google Scholar
• Frohling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002;100(13):4372–4380.
   PubMed Web of Science ®Google Scholar
• Abu-Duhier FM, Goodeve AC, Wilson GA, et al. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol. 2001;113(4):983–988.
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001;97(8):2434–2439.
   PubMed Web of Science ®Google Scholar
• Reindl C, Bagrintseva K, Vempati S, et al. Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML. Blood. 2006;107(9):3700–3707.
   PubMed Web of Science ®Google Scholar
• Frohling S, Scholl C, Levine RL, et al. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell. 2007;12(6):501–513.
   PubMed Web of Science ®Google Scholar
• Breitenbuecher F, Schnittger S, Grundler R, et al. Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor. Blood. 2009;113(17):4074–4077.
   PubMed Web of Science ®Google Scholar
• Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99(12):4326–4335.
   PubMed Web of Science ®Google Scholar
• Grundler R, Thiede C, Miething C, et al. Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor. Blood. 2003;102(2):646–651.
   PubMed Web of Science ®Google Scholar
• Radomska HS, Alberich-Jorda M, Will B, et al. Targeting CDK1 promotes FLT3-activated acute myeloid leukemia differentiation through C/EBPalpha. J Clin Invest. 2012;122(8):2955–2966.
   PubMed Web of Science ®Google Scholar
• Reiter K, Polzer H, Krupka C, et al. Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia. Leukemia. 2018;32(2):313–322.
   PubMed Web of Science ®Google Scholar
• Kayser S, Schlenk RF, Londono MC, et al. Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood. 2009;114(12):2386–2392.
   PubMed Web of Science ®Google Scholar
• Marhäll A, Heidel F, Fischer T, et al. Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation. Ann Hematol. 2018;97(5):773–780.
   PubMed Web of Science ®Google Scholar
• Cloos J, Goemans BF, Hess CJ, et al. Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Leukemia. 2006;20(7):1217–1220.
   PubMed Web of Science ®Google Scholar
• Ozeki K, Kiyoi H, Hirose Y, et al. Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood. 2004;103(5):1901–1908.
   PubMed Web of Science ®Google Scholar
• Garcia JS, Stone RM. The development of FLT3 inhibitors in acute myeloid leukemia. Hematol Oncol Clin North Am. 2017;31(4):663–680.
   PubMed Web of Science ®Google Scholar
• Zhang B, Duran PA, Piechaczyk L, et al. GRP94 rewires and buffers the FLT3-ITD signaling network and promotes survival of acute myeloid leukemic stem cells. Haematologica. 2018;104(5):e229.
   Web of Science ®Google Scholar
• Tiong IS, Wei AH. New drugs creating new challenges in acute myeloid leukemia. Genes Chromosomes Cancer. 2019. doi:10.1002/gcc.22750.
   PubMed Web of Science ®Google Scholar
• Jensen ON. Interpreting the protein language using proteomics. Nat Rev Mol Cell Biol. 2006;7(6):391–403.
   PubMed Web of Science ®Google Scholar
• Helenius A, Aebi M. Intracellular functions of N-linked glycans. Science ( New York, NY). 2001;291(5512):2364–2369.
   PubMed Web of Science ®Google Scholar
• Rudd PM, Elliott T, Cresswell P, et al. Glycosylation and the immune system. Science ( New York, NY). 2001;291(5512):2370–2376.
   PubMed Web of Science ®Google Scholar
• Wiederschain GY. Glycobiology: progress, problems, and perspectives. Biochem Biokhimiia. 2013;78(7):679–696.
   PubMed Web of Science ®Google Scholar
• Maeda Y, Kinoshita T. Dolichol-phosphate mannose synthase: structure, function and regulation. Biochimica et biophysica acta. 2008;1780(6):861–868.
   PubMed Web of Science ®Google Scholar
• Larrue C, Saland E, Vergez F, et al. Antileukemic activity of 2-deoxy-d-glucose through inhibition of N-linked glycosylation in acute myeloid leukemia with FLT3-ITD or c-KIT mutations. Mol Cancer Ther. 2015;14(10):2364–2373.
   PubMed Web of Science ®Google Scholar
• Keenan RW, Hamill RL, Occolowitz JL, et al. Biological activities of isolated tunicamycin and streptovirudin fractions. Biochemistry. 1981;20(10):2968–2973.
   PubMed Web of Science ®Google Scholar
• Heifetz A, Keenan RW, Elbein AD. Mechanism of action of tunicamycin on the UDP-GlcNAc:dolichyl-phosphate Glc-NAc-1-phosphate transferase. Biochemistry. 1979;18(11):2186–2192.
   PubMed Web of Science ®Google Scholar
• Lyman SD, James L, Vanden Bos T, et al. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell. 1993;75(6):1157–1167.
   PubMed Web of Science ®Google Scholar
• Lavagna-Sevenier C, Marchetto S, Birnbaum D, et al. FLT3 signaling in hematopoietic cells involves CBL, SHC and an unknown P115 as prominent tyrosine-phosphorylated substrates. Leukemia. 1998;12(3):301–310.
   PubMed Web of Science ®Google Scholar
• Rosnet O, Buhring HJ, deLapeyriere O, et al. Expression and signal transduction of the FLT3 tyrosine kinase receptor. Acta haematologica. 1996;95(3–4):218–223.
   PubMed Web of Science ®Google Scholar
• Zhang S, Broxmeyer HE. Flt3 ligand induces tyrosine phosphorylation of gab1 and gab2 and their association with shp-2, grb2, and PI3 kinase. Biochem Biophys Res Commun. 2000;277(1):195–199.
   PubMed Web of Science ®Google Scholar
• Kim KT, Baird K, Ahn JY, et al. Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Blood. 2005;105(4):1759–1767.
   PubMed Web of Science ®Google Scholar
• Tse KF, Mukherjee G, Small D. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia. 2000;14(10):1766–1776.
   PubMed Web of Science ®Google Scholar
• Koch S, Jacobi A, Ryser M, et al. Abnormal localization and accumulation of FLT3-ITD, a mutant receptor tyrosine kinase involved in leukemogenesis. Cells Tissues Organs (Print). 2008;188(1–2):225–235.
   PubMed Web of Science ®Google Scholar
• Choudhary C, Olsen JV, Brandts C, et al. Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell. 2009;36(2):326–339.
   PubMed Web of Science ®Google Scholar
• Mizuki M, Fenski R, Halfter H, et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood. 2000;96(12):3907–3914.
   PubMed Web of Science ®Google Scholar
• Grundler R, Miething C, Thiede C, et al. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. Blood. 2005;105(12):4792–4799.
   PubMed Web of Science ®Google Scholar
• Muller-Tidow C, Steur C, Mizuki M, et al. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms]. Deutsche medizinische Wochenschrift ( 1946). 2002;127(42):2195–2200.
   PubMed Web of Science ®Google Scholar
• Choudhary C, Muller-Tidow C, Berdel WE, et al. Signal transduction of oncogenic Flt3. Int J Hematol. 2005;82(2):93–99.
   PubMed Web of Science ®Google Scholar
• Choudhary C, Brandts C, Schwable J, et al. Activation mechanisms of STAT5 by oncogenic Flt3-ITD. Blood. 2007;110(1):370–374.
   PubMed Web of Science ®Google Scholar
• Murata K, Kumagai H, Kawashima T, et al. Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3). J Biol Chem. 2003;278(35):32892–32898.
   PubMed Web of Science ®Google Scholar
• Sallmyr A, Fan J, Datta K, et al. Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML. Blood. 2008;111(6):3173–3182.
   PubMed Web of Science ®Google Scholar
• Brown J. Effects of 2-deoxyglucose on carbohydrate metablism: review of the literature and studies in the rat. Metab Clin Exp. 1962;11:1098–1112.
   PubMed Web of Science ®Google Scholar
• Kang HT, Hwang ES. 2-Deoxyglucose: an anticancer and antiviral therapeutic, but not any more a low glucose mimetic. Life Sci. 2006;78(12):1392–1399.
   PubMed Web of Science ®Google Scholar
• Pelicano H, Martin DS, Xu RH, et al. Glycolysis inhibition for anticancer treatment. Oncogene. 2006;25(34):4633–4646.
   PubMed Web of Science ®Google Scholar
• Ellgaard L, Helenius A. Quality control in the endoplasmic reticulum. Nat Rev Mol Cell Biol. 2003;4(3):181–191.
   PubMed Web of Science ®Google Scholar
• Parodi AJ. Protein glucosylation and its role in protein folding. Annu Rev Biochem. 2000;69:69–93.
   PubMed Web of Science ®Google Scholar
• Andresen L, Skovbakke SL, Persson G, et al. 2-deoxy D-glucose prevents cell surface expression of NKG2D ligands through inhibition of N-linked glycosylation. J Immunol ( Baltimore, Md: 1950). 2012;188(4):1847–1855.
   PubMed Web of Science ®Google Scholar
• Kurtoglu M, Gao N, Shang J, et al. Under normoxia, 2-deoxy-D-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation. Mol Cancer Ther. 2007;6(11):3049–3058.
   PubMed Web of Science ®Google Scholar
• Xi H, Kurtoglu M, Liu H, et al. 2-Deoxy-D-glucose activates autophagy via endoplasmic reticulum stress rather than ATP depletion. Cancer Chemother Pharmacol. 2011;67(4):899–910.
   PubMed Web of Science ®Google Scholar
• Kang HT, Ju JW, Cho JW, et al. Down-regulation of Sp1 activity through modulation of O-glycosylation by treatment with a low glucose mimetic, 2-deoxyglucose. J Biol Chem. 2003;278(51):51223–51231.
   PubMed Web of Science ®Google Scholar
• Han X, Zhang X, Li H, et al. Tunicamycin enhances the antitumor activity of Trastuzumab on breast cancer in vitro and in vivo. Oncotarget. 2015;6(36):38912–38925.
   PubMedGoogle Scholar
• Contessa JN, Bhojani MS, Freeze HH, et al. Molecular imaging of N-linked glycosylation suggests glycan biosynthesis is a novel target for cancer therapy. Clin Cancer Research: Official J Am Assoc Cancer Res. 2010;16(12):3205–3214.
   PubMed Web of Science ®Google Scholar
• Contessa JN, Bhojani MS, Freeze HH, et al. Inhibition of N-linked glycosylation disrupts receptor tyrosine kinase signaling in tumor cells. Cancer Res. 2008;68(10):3803–3809.
   PubMed Web of Science ®Google Scholar
• Ahsan A, Hiniker SM, Ramanand SG, et al. Role of epidermal growth factor receptor degradation in cisplatin-induced cytotoxicity in head and neck cancer. Cancer Res. 2010;70(7):2862–2869.
   PubMed Web of Science ®Google Scholar
• Helenius A, Aebi M. Roles of N-linked glycans in the endoplasmic reticulum. Annu Rev Biochem. 2004;73:1019–1049.
   PubMed Web of Science ®Google Scholar
• Ahmmed B, Khan MN, Nisar MA, et al. Tunicamycin enhances the suppressive effects of cisplatin on lung cancer growth through PTX3 glycosylation via AKT/NF-kappaB signaling pathway. Int J Oncol. 2019;54(2):431–442.
   PubMed Web of Science ®Google Scholar
• Tsitsipatis D, Jayavelu AK, Muller JP, et al. Synergistic killing of FLT3ITD-positive AML cells by combined inhibition of tyrosine-kinase activity and N-glycosylation. Oncotarget. 2017;8(16):26613–26624.
   PubMedGoogle Scholar
• Corsini A, Maggi FM, Catapano AL. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol Res. 1995;31(1):9–27.
   PubMed Web of Science ®Google Scholar
• Mo H, Elson CE. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Biol Med ( Maywood. NJ). 2004;229(7):567–585.
   PubMed Web of Science ®Google Scholar
• Stirewalt DL, Appelbaum FR, Willman CL, et al. Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression. Leuk Res. 2003;27(2):133–145.
   PubMed Web of Science ®Google Scholar
• Lee J, Lee I, Han B, et al. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. J Natl Cancer Inst. 2011;103(8):674–688.
   PubMed Web of Science ®Google Scholar
• Martirosyan A, Clendening JW, Goard CA, et al. Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance. BMC Cancer. 2010;10(103). doi:10.1186/1471-2407-10-103.
   Web of Science ®Google Scholar
• Holstein SA, Knapp HR, Clamon GH, et al. Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies. Cancer Chemother Pharmacol. 2006;57(2):155–164.
   PubMed Web of Science ®Google Scholar
• Hamadmad SN, Hohl RJ. Lovastatin suppresses erythropoietin receptor surface expression through dual inhibition of glycosylation and geranylgeranylation. Biochem Pharmacol. 2007;74(4):590–600.
   PubMed Web of Science ®Google Scholar
• Yoshimura A, D’Andrea AD, Lodish HF. Friend spleen focus-forming virus glycoprotein gp55 interacts with the erythropoietin receptor in the endoplasmic reticulum and affects receptor metabolism. Proc Natl Acad Sci U.S.A. 1990;87(11):4139–4143.
   PubMed Web of Science ®Google Scholar
• Siddals KW, Marshman E, Westwood M, et al. Abrogation of insulin-like growth factor-I (IGF-I) and insulin action by mevalonic acid depletion: synergy between protein prenylation and receptor glycosylation pathways. J Biol Chem. 2004;279(37):38353–38359.
   PubMed Web of Science ®Google Scholar
• Tahvanainen J, Kylaniemi MK, Kanduri K, et al. Proviral integration site for moloney murine leukemia virus (PIM) kinases promote human T helper 1 cell differentiation. J Biol Chem. 2013;288(5):3048–3058.
   PubMed Web of Science ®Google Scholar
• Xie Y, Burcu M, Linn DE, et al. Pim-1 kinase protects P-glycoprotein from degradation and enables its glycosylation and cell surface expression. Mol Pharmacol. 2010;78(2):310–318.
   PubMed Web of Science ®Google Scholar
• Bullock AN, Debreczeni J, Amos AL, et al. Structure and substrate specificity of the Pim-1 kinase. J Biol Chem. 2005;280(50):41675–41682.
   PubMed Web of Science ®Google Scholar
• Kamemura K, Hart GW. Dynamic interplay between O-glycosylation and O-phosphorylation of nucleocytoplasmic proteins: a new paradigm for metabolic control of signal transduction and transcription. Prog Nucleic Acid Res Mol Biol. 2003;73:107–136.
   PubMed Web of Science ®Google Scholar
• Natarajan K, Xie Y, Burcu M, et al. Pim-1 kinase phosphorylates and stabilizes 130 kDa FLT3 and promotes aberrant STAT5 signaling in acute myeloid leukemia with FLT3 internal tandem duplication. PloS one. 2013;8(9):e74653.
   PubMed Web of Science ®Google Scholar
• Marzec M, Eletto D, Argon Y. GRP94: an HSP90-like protein specialized for protein folding and quality control in the endoplasmic reticulum. Biochimica et biophysica acta. 2012;1823(3):774–787.
   PubMed Web of Science ®Google Scholar
• Rutherford SL, Lindquist S. Hsp90 as a capacitor for morphological evolution. Nature. 1998;396(6709):336–342.
   PubMed Web of Science ®Google Scholar
• Trepel J, Mollapour M, Giaccone G, et al. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer. 2010;10(8):537–549.
   PubMed Web of Science ®Google Scholar
• Minami Y, Kiyoi H, Yamamoto Y, et al. Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors. Leukemia. 2002;16(8):1535–1540.
   PubMed Web of Science ®Google Scholar
• Taldone T, Patel PD, Patel M, et al. Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series. J Med Chem. 2013;56(17):6803–6818.
   PubMed Web of Science ®Google Scholar
• Weisberg E, Boulton C, Kelly LM, et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell. 2002;1(5):433–443.
   PubMed Web of Science ®Google Scholar
• Wolfert MA, Boons GJ. Adaptive immune activation: glycosylation does matter. Nat Chem Biol. 2013;9(12):776–784.
   PubMed Web of Science ®Google Scholar
• von Bubnoff N, Engh RA, Aberg E, et al. FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro. Cancer Res. 2009;69(7):3032–3041.
   PubMed Web of Science ®Google Scholar